title: Gestational trophoblastic disease: a 21-year review of the clinical experience at an Argentinean public hospital.
abstract: OBJECTIVE
  To analyze the clinical trends of gestational trophoblastic disease (GTD) in a public hospital of Buenos Aires, Argentina.
  
  
  METHODS
  A review of the clinical records of 358 patients with a diagnosis of GTD admitted to Durand Trophoblastic Disease Center between 1990 and February 2011 was performed. Features of diagnosis, treatment and follow-up were analyzed.
  
  
  RESULTS
  A total of 358 cases of GTD were reviewed. Hydatidiform mole was diagnosed in 340 patients; of those 223 (66%) experienced spontaneous remission after evacuation. Of the 135 patients with persistent gestational trophoblastic neoplasia (GTN), 99 (73%) had low-risk GTN, 32 (26%) had high-risk GTN and 4 had either placental site trophoblastic disease or epithelioid trophoblastic tumor. In the low-risk group the first-line treatment was methotrexate and the second-line treatment was actinomycin D, etoposide, cytoxan, and oncovin (EMA/CO), with a complete response rate of 100%. High-risk patients whose WHO prognostic scores were 7-13 were treated initially with EMA/CO. Patients whose scores were >13 were treated with EMA/PE, where platinum and etoposide replaced oncovin and cytoxan. Salvage therapy in patients with relapse or resistant disease were treated with a wide variety of chemotherapy regimens. The complete response rate was 98.2%. Compliance was 100%. Three patients died. In all cases the outcome was related with inadequate initial treatment.
  
  
  CONCLUSIONS
  This protocol is in agreement with international consensus. It was useful, safe and feasible in our population. The compliance with international guidelines allows reach a successful treatment and follow-up in one Latin-American population.
authors: Clinical Oncology Unit, Department of Gynecology and Obstetrics, Durand Hospital, Buenos Aires, Argentina. molaetgdurand@gmail.com
authors: Maria Inés
authors: MI
authors: Bianconi
authors: Silvina
authors: S
authors: Otero
authors: Oriana
authors: O
authors: Moscheni
authors: Lucia
authors: L
authors: Alvarez
authors: Claudio
authors: C
authors: Storino
authors: Gustavo
authors: G
authors: Jankilevich
mesh_terms: D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001118:Argentina / Q000453:epidemiology; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D006779:Hospitals, Public; D006801:Humans; D007044:Hysterectomy; D002955:Leucovorin / Q000008:administration & dosage; D008137:Longitudinal Studies; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011247:Pregnancy; D012075:Remission, Spontaneous; D012189:Retrospective Studies; D018570:Risk Assessment; D016879:Salvage Therapy; D014594:Uterine Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D014619:Vacuum Curettage; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; D009944:Organoplatinum Compounds; D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D002955:Leucovorin; D008727:Methotrexate